CAS 820232-50-6

Pasireotide (aspartate)

Description:

Pasireotide (aspartate) is a synthetic cyclic octapeptide and a somatostatin analog, primarily used in the treatment of acromegaly and Cushing's disease. It functions by binding to somatostatin receptors, particularly subtype 5, inhibiting the secretion of growth hormone and adrenocorticotropic hormone (ACTH). This action helps to regulate hormonal imbalances associated with these conditions. Pasireotide exhibits a unique pharmacological profile, with a broader receptor binding affinity compared to natural somatostatin, which enhances its therapeutic efficacy. The substance is typically administered via subcutaneous injection and has a relatively long half-life, allowing for less frequent dosing. Its solubility characteristics are influenced by its aspartate salt form, which aids in its formulation for clinical use. Common side effects may include gastrointestinal disturbances, hyperglycemia, and potential impacts on liver function. Overall, pasireotide (aspartate) represents a significant advancement in the management of specific endocrine disorders, providing an alternative for patients who do not respond adequately to other treatments.

Formula: C₆₆H₈₀N₁₂O₁₇

Synonyms:

• trade name: Signifor
• Pasireotide (aspartate)
• Signifor LAR

Pasireotide diaspartate

CAS: 820232-50-6

Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs.

Formula: C₆₆H₈₀N₁₂O₁₇

Color and Shape: Solid

Molecular weight: 1313.433

Ref: TM-T28298

Pasireotide Aspartate

CAS: 820232-50-6

Formula: C₅₈H₆₆N₁₀O₉·2C₄H₇NO₄

Molecular weight: 1047.23 2*133.10

Ref: 4Z-PP-266003

Parireotide diaspartate

CAS: 820232-50-6

Parireotide diaspartate is a peptide that belongs to the group of activators and is used as a research tool. It can be used to activate different ion channels, such as calcium channels. In cell biology, it has been shown to inhibit protein interactions and receptor-ligand binding. Parireotide diaspartate has also been reported to have pharmacological properties, including the ability to inhibit protein synthesis and act as an antagonist at glutamate receptors.

Formula: C₆₆H₈₀N₁₂O₁₇

Purity: Min. 95%

Molecular weight: 1,313.4 g/mol

Ref: 3D-VHB23250

Pasireotide Aspartate

CAS: 820232-50-6

Formula: C₅₈H₆₆N₁₀O₉(C₄H₇NO₄)

Molecular weight: 1047.23 : 2(133.10)

Ref: ST-EA-CP-P158016